Lupin Expects Respiratory Ramp Up From Fiscal '22
Generics To Benefit From US Election Outcome
After launching albuterol, India's Lupin is seeking to expand its presence in the respiratory market. With generic Fostair set for a European launch in fiscal 2022 and Spiriva for a US introduction the following fiscal year, the company is counting on the portfolio to deliver growth from the coming financial year.
You may also be interested in...
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
With global rights to TTP's soft-mist inhalation platform, Lupin gets access to the drug delivery system used by Boehringer Ingelheim for Spiriva Respimat and it will be interesting to watch pricing as Lupin leverages the aerosolization technology across respiratory products. Meanwhile, the company has entered a partnership with Biomm for marketing its Neulasta biosimilar in Brazil.
Buoyed by a $50m milestone payment for a MEK inhibitor licensed to Boehringer Ingelheim and in a bid to mitigate the burn on profits, Lupin is considering partnerships for biosimilars, specialty products and other NCEs with recently spun-off oncology assets being first in line for a deal. But FY22 earnings guidance has been lowered.